Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402493 | 0.88 | RIPK1 (0.35) | — | |
| SCHEMBL17955227 | 0.86 | P2RX7 (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1547515 | 0.78 | ALDH1A1 (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31160546 | 0.77 | CD38 (0.40) | — | |
| SCHEMBL91355 | 0.76 | TSHR (0.38) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12658944 | 0.76 | HTR2A (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL25370870 | 0.74 | HTR2A (0.32) | — | |
| SCHEMBL10937568 | 0.74 | CYP3A4 (0.50) | — | |
| SCHEMBL5413173 | 0.74 | — | — | |
| SCHEMBL25370371 | 0.74 | IDO1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941906-B1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACUETICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20100160411-A1 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | disclosed |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, SLC10A1, FXR1 | GRIN2D 1203/4885GRIN3B 470/4885GRIN1 754/4885 |
| US-20100160411-A1 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | HTR2C, HTR3B, HTR1A | GRIN2D 203/4885GRIN3B 206/4885GRIN1 237/4885 |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | HTR1A, HTR2C, CHRM1 | GRIN2D 319/4885GRIN3B 202/4885GRIN1 305/4885 |
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | GRIN2D 3142/4885GRIN3B 3454/4885GRIN1 2905/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | GRIN2D 2446/4885GRIN3B 2882/4885GRIN1 2739/4885 |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HTR2C, HTR5A, NPY1R | GRIN2D 178/4885GRIN3B 210/4885GRIN1 203/4885 |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, SLC10A1, FXR1 | GRIN2D 1203/4885GRIN3B 470/4885GRIN1 754/4885 |
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | GRIN2D 1446/4885GRIN3B 2348/4885GRIN1 2194/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | GRIN2D 1785/4885GRIN3B 610/4885GRIN1 1857/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | GRIN2D 1446/4885GRIN3B 2348/4885GRIN1 2194/4885 |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | GRIN2D 4045/4885GRIN3B 3621/4885GRIN1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.